A view on redefining key roles across the evolving clinical development landscape.
The EU has announced a new regulation - number 536/2014 - for clinical trials, which is planned to come into force not before 28th May 2016. It is an important step because it sets out the requirements for a single clinical trial approval portal and the content of clinical trial applications to be standardized.
The primary objectives of GCP are to protect the safety, rights, and welfare of subjects, and to ensure the credibility of trial data and resulting reports.
Conducting Large Simple Trials to answer questions about "real-world" medical interventions is not a recent concept.
Virtual CRA meetings hold a lot of potential, but work still needs to be done to ensure effectiveness.
Industry benefits from heightened innovation, site/sponsor relationships, and diversity.
How iterative analysis of subject recruitment data can optimize outcomes during ongoing enrollment.
A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.
When we hear about a new blockbuster drug coming to market, we usually think about a medical treatment.
Examining why newly registered trials have fallen in Central and Eastern Europe, relative to other regions.
One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.
The use of RBM may be the only way forward as long as the development of medicines relies on clinical testing.
A systematic approach for early identification of BP effects during development of new drugs.
Differing levels of trust in clinical trials information channels across diverse populations is examined in this research.
How to satisfy regulatory concerns about EDC data integrity and site controls over its source records.
The primary objectives of GCP are to protect the safety, rights, and welfare of subjects, and to ensure the credibility of trial data and resulting reports.
The excessive cost of clinical trials mixed with the inefficiency of clinical trial management is a widespread problem among research institutions.
Conducting Large Simple Trials to answer questions about "real-world" medical interventions is not a recent concept.
A "can’t live with them, can’t live without them" attitude is revealed in survey of standard operating procedures in the management and conduct of clinical trials.
A "can’t live with them, can’t live without them" attitude is revealed in survey of standard operating procedures in the management and conduct of clinical trials.
The use of RBM may be the only way forward as long as the development of medicines relies on clinical testing.
Clinical research is complicated, and it?s not just the science. Take CDASH, CDISC and E2B for example. Aren?t acronyms awesome?
Patient consent is important to stay on top of for many reasons.
The dilemma facing clinical operations executives when selecting a CTMS solution to manage clinical trials is to go with an existing approach/solution or explore alternative options.
Survey appraises the use of SOPs in clinical research from the sponsors' point of view.
With all of the buzz and excitement around risk-based monitoring, one might expect that the broad adoption of this emerging clinical research paradigm is well under way.
Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.
How iterative analysis of subject recruitment data can optimize outcomes during ongoing enrollment.